Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
NCT01224717
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
104
Enrollment
INDUSTRY
Sponsor class
Conditions
Post-menopausal Osteoporosis
Interventions
DRUG:
PTH134
DRUG:
Placebo
DRUG:
Forsteo
Sponsor
Novartis